Physician profile
Christopher Michael Ferrell
NPI 1528592516
$842.34
in general payments reported to CMS, 2019-2025
20 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.64 · 2021: $210 · 2022: $92.41 · 2023: $80.02 · 2024: $201 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $116.13 | 2021 | |
| Amgen INC. | $106.40 | 2020-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $104.89 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $59.98 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $58.00 | 2022-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Harmony Biosciences LLC | $48.99 | 2025 | |
| Pfizer INC. | $41.77 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.49 | 2020-2021 | |
| Exact Sciences Corporation | $31.79 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $29.66 | 2024 | Vivitrol |
| Indivior INC. | $29.01 | 2024 | Sublocade |
| Astrazeneca Pharmaceuticals Lp | $28.13 | 2025 | Airsupra |
| Lundbeck LLC | $27.36 | 2022-2023 | Rexulti |
| Glaxosmithkline, LLC. | $18.89 | 2024 | Arexvy |
| Sanofi Pasteur INC. | $18.23 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.50 | 2025 | Watchman Flx |
| Lilly USA, LLC | $16.83 | 2020 | |
| Dexcom, INC. | $16.03 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $16.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.